AAO 2025: 12-month outcomes of travoprost intracameral implant (iDose TR) in conjunction with cataract surgery

Inder Paul Singh, a glaucoma anterior segment surgeon from southeastern Wisconsin, presented his clinical experience and a study involving the travaprost intracameral implant combined with cataract surgery. He shared insights from his work in Armenia and subsequent research, focusing on the effectiveness and safety of the iDose implant, which releases travoprost oil to lower intraocular pressure (IOP) in glaucoma patients.

The study highlighted that patients had an unmedicated baseline IOP of about 25 mmHg. Following cataract surgery with the iDose implant, there was an average IOP reduction of 11 mmHg after 12 months. Notably, 98% of patients experienced at least a 20% drop in IOP from baseline, and over 96% achieved pressures under 18 mmHg. Most participants were medication-free post-surgery, and none required more than one topical drop.

Singh emphasized the procedure’s safety, noting the absence of clinically significant cystoid macular edema (CME) or chronic inflammation over the year-long study. The standard post-op steroid taper used in cataract care sufficed, and there were no heightened risks commonly associated with prostaglandin use during eye surgery.

A key takeaway was the high confidence this option gives surgeons—having predictable, significant IOP reduction safely and efficiently. Dr. Singh pointed out the quick learning curve of the procedure, as it does not require complex cannulation; this makes it approachable for surgeons less familiar with minimally invasive glaucoma surgeries (MIGS). Additionally, the iDose can be combined with various MIGS for patients needing further pressure reduction.

In summary, Singh’s experience and research support the iDose implant’s effectiveness and safety when used with cataract surgery, providing a valuable option for ophthalmologists aiming to achieve reliable, medication-sparing outcomes for glaucoma patients.